| node1 | node2 | node1 accession | node2 accession | node1 annotation | node2 annotation | score |
| ANXA8 | TCF3 | ENSP00000341674 | ENSP00000262965 | annexin A8 | transcription factor 3 (E2A immunoglobulin enhancer binding factors E12/E47); Transcriptional regulator. Involved in the initiation of neuronal differentiation. Heterodimers between TCF3 and tissue- specific basic helix-loop-helix (bHLH) proteins play major roles in determining tissue-specific cell fate during embryogenesis, like muscle or early B-cell differentiation. Dimers bind DNA on E- box motifs- 5’-CANNTG-3’. Binds to the kappa-E2 site in the kappa immunoglobulin gene enhancer. Binds to IEB1 and IEB2, which are short DNA sequences in the insulin gene transcription control region | 0.607 |
| ANXA8 | TFPT | ENSP00000341674 | ENSP00000375639 | annexin A8 | TCF3 (E2A) fusion partner (in childhood Leukemia) | 0.564 |
| ANXA8L1 | TCF3 | ENSP00000352101 | ENSP00000262965 | annexin A8-like 1 | transcription factor 3 (E2A immunoglobulin enhancer binding factors E12/E47); Transcriptional regulator. Involved in the initiation of neuronal differentiation. Heterodimers between TCF3 and tissue- specific basic helix-loop-helix (bHLH) proteins play major roles in determining tissue-specific cell fate during embryogenesis, like muscle or early B-cell differentiation. Dimers bind DNA on E- box motifs- 5’-CANNTG-3’. Binds to the kappa-E2 site in the kappa immunoglobulin gene enhancer. Binds to IEB1 and IEB2, which are short DNA sequences in the insulin gene transcription control region | 0.607 |
| ANXA8L1 | TFPT | ENSP00000352101 | ENSP00000375639 | annexin A8-like 1 | TCF3 (E2A) fusion partner (in childhood Leukemia) | 0.564 |
| ANXA8L2 | TCF3 | ENSP00000363395 | ENSP00000262965 | annexin A8-like 2 | transcription factor 3 (E2A immunoglobulin enhancer binding factors E12/E47); Transcriptional regulator. Involved in the initiation of neuronal differentiation. Heterodimers between TCF3 and tissue- specific basic helix-loop-helix (bHLH) proteins play major roles in determining tissue-specific cell fate during embryogenesis, like muscle or early B-cell differentiation. Dimers bind DNA on E- box motifs- 5’-CANNTG-3’. Binds to the kappa-E2 site in the kappa immunoglobulin gene enhancer. Binds to IEB1 and IEB2, which are short DNA sequences in the insulin gene transcription control region | 0.607 |
| ANXA8L2 | TFPT | ENSP00000363395 | ENSP00000375639 | annexin A8-like 2 | TCF3 (E2A) fusion partner (in childhood Leukemia) | 0.564 |
| EAF1 | ELL | ENSP00000380054 | ENSP00000262809 | ELL associated factor 1; Acts as a transcriptional transactivator of ELL and ELL2 elongation activities | elongation factor RNA polymerase II; Elongation factor component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA. ELL also plays an early role before its assembly into in the SEC complex by stabilizing RNA polymerase II recruitment/initiation and entry into the pause site. Required to stabilize the pre- initiation complex and early elongation | 0.996 |
| EAF1 | TFPT | ENSP00000380054 | ENSP00000375639 | ELL associated factor 1; Acts as a transcriptional transactivator of ELL and ELL2 elongation activities | TCF3 (E2A) fusion partner (in childhood Leukemia) | 0.567 |
| EAF2 | ELL | ENSP00000273668 | ENSP00000262809 | ELL associated factor 2; Acts as a transcriptional transactivator of TCEA1 elongation activity (By similarity). Acts as a transcriptional transactivator of ELL and ELL2 elongation activities. Potent inducer of apoptosis in prostatic and non-prostatic cell lines. Inhibits prostate tumor growth in vivo | elongation factor RNA polymerase II; Elongation factor component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA. ELL also plays an early role before its assembly into in the SEC complex by stabilizing RNA polymerase II recruitment/initiation and entry into the pause site. Required to stabilize the pre- initiation complex and early elongation | 0.995 |
| EAF2 | TFPT | ENSP00000273668 | ENSP00000375639 | ELL associated factor 2; Acts as a transcriptional transactivator of TCEA1 elongation activity (By similarity). Acts as a transcriptional transactivator of ELL and ELL2 elongation activities. Potent inducer of apoptosis in prostatic and non-prostatic cell lines. Inhibits prostate tumor growth in vivo | TCF3 (E2A) fusion partner (in childhood Leukemia) | 0.567 |
| ELL | EAF1 | ENSP00000262809 | ENSP00000380054 | elongation factor RNA polymerase II; Elongation factor component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA. ELL also plays an early role before its assembly into in the SEC complex by stabilizing RNA polymerase II recruitment/initiation and entry into the pause site. Required to stabilize the pre- initiation complex and early elongation | ELL associated factor 1; Acts as a transcriptional transactivator of ELL and ELL2 elongation activities | 0.996 |
| ELL | EAF2 | ENSP00000262809 | ENSP00000273668 | elongation factor RNA polymerase II; Elongation factor component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA. ELL also plays an early role before its assembly into in the SEC complex by stabilizing RNA polymerase II recruitment/initiation and entry into the pause site. Required to stabilize the pre- initiation complex and early elongation | ELL associated factor 2; Acts as a transcriptional transactivator of TCEA1 elongation activity (By similarity). Acts as a transcriptional transactivator of ELL and ELL2 elongation activities. Potent inducer of apoptosis in prostatic and non-prostatic cell lines. Inhibits prostate tumor growth in vivo | 0.995 |
| ELL | TFPT | ENSP00000262809 | ENSP00000375639 | elongation factor RNA polymerase II; Elongation factor component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA. ELL also plays an early role before its assembly into in the SEC complex by stabilizing RNA polymerase II recruitment/initiation and entry into the pause site. Required to stabilize the pre- initiation complex and early elongation | TCF3 (E2A) fusion partner (in childhood Leukemia) | 0.567 |
| NOL3 | PRPF31 | ENSP00000268605 | ENSP00000324122 | nucleolar protein 3 (apoptosis repressor with CARD domain); Isoform 1 may be involved in RNA splicing | PRP31 pre-mRNA processing factor 31 homolog (S. cerevisiae) | 0.459 |
| NOL3 | TFPT | ENSP00000268605 | ENSP00000375639 | nucleolar protein 3 (apoptosis repressor with CARD domain); Isoform 1 may be involved in RNA splicing | TCF3 (E2A) fusion partner (in childhood Leukemia) | 0.576 |
| PAWR | TFPT | ENSP00000328088 | ENSP00000375639 | PRKC, apoptosis, WT1, regulator; Pro-apoptopic protein capable of selectively inducing apoptosis in cancer cells, sensitizing the cells to diverse apoptotic stimuli and causing regression of tumors in animal models. Induces apoptosis in certain cancer cells by activation of the Fas prodeath pathway and coparallel inhibition of NF-kappa-B transcriptional activity. Inhibits the transcriptional activation and augments the transcriptional repression mediated by WT1. Down- regulates the anti-apoptotic protein BCL2 via its interaction with WT1. Seems also to be a transcriptional repressor by [...] | TCF3 (E2A) fusion partner (in childhood Leukemia) | 0.576 |
| PRPF31 | NOL3 | ENSP00000324122 | ENSP00000268605 | PRP31 pre-mRNA processing factor 31 homolog (S. cerevisiae) | nucleolar protein 3 (apoptosis repressor with CARD domain); Isoform 1 may be involved in RNA splicing | 0.459 |
| PRPF31 | TFPT | ENSP00000324122 | ENSP00000375639 | PRP31 pre-mRNA processing factor 31 homolog (S. cerevisiae) | TCF3 (E2A) fusion partner (in childhood Leukemia) | 0.662 |
| TCF3 | ANXA8 | ENSP00000262965 | ENSP00000341674 | transcription factor 3 (E2A immunoglobulin enhancer binding factors E12/E47); Transcriptional regulator. Involved in the initiation of neuronal differentiation. Heterodimers between TCF3 and tissue- specific basic helix-loop-helix (bHLH) proteins play major roles in determining tissue-specific cell fate during embryogenesis, like muscle or early B-cell differentiation. Dimers bind DNA on E- box motifs- 5’-CANNTG-3’. Binds to the kappa-E2 site in the kappa immunoglobulin gene enhancer. Binds to IEB1 and IEB2, which are short DNA sequences in the insulin gene transcription control region | annexin A8 | 0.607 |
| TCF3 | ANXA8L1 | ENSP00000262965 | ENSP00000352101 | transcription factor 3 (E2A immunoglobulin enhancer binding factors E12/E47); Transcriptional regulator. Involved in the initiation of neuronal differentiation. Heterodimers between TCF3 and tissue- specific basic helix-loop-helix (bHLH) proteins play major roles in determining tissue-specific cell fate during embryogenesis, like muscle or early B-cell differentiation. Dimers bind DNA on E- box motifs- 5’-CANNTG-3’. Binds to the kappa-E2 site in the kappa immunoglobulin gene enhancer. Binds to IEB1 and IEB2, which are short DNA sequences in the insulin gene transcription control region | annexin A8-like 1 | 0.607 |
Share
